|
AMLX Amylyx Pharmaceuticals Inc 1658551 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-43,423,000.00 |
| Balance Sheet |
|
Current Assets
|
$256,338,000.00 |
|
Assets
|
$264,564,000.00 |
|
Current Liabilities
|
$21,150,000.00 |
|
Liabilities
|
$25,397,000.00 |
|
Equity
|
$239,167,000.00 |
|
Shares Out
|
111368283.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-68,306,000.00 |
|
Investing Cash Flow
|
$-113,535,000.00 |
| Market Analysis |
Market Cap
|
$4,416,866,103.78 |
|
Price
|
$32.41 |
|
BVPS
|
2.15 |
|
PB
|
18.45 |
|
EPS
|
-0.39 |
|
FCF
|
$-103,406,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:31 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:22 |
|
| Apr |
May |
Jun |
| 2026-03-03 |
-0.30 |
|
|
2026-05-07 |
-0.37 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-07 |
-0.46 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-06 |
-0.37 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view AMLX documents filed with the SEC.
AMLX Filings
Clear
